NKF(SH:603707) Mei Ri Jing Ji Xin Wen·2025-10-24 12:40Group 1 - The core point of the article is that Jianyou Co., Ltd. (SH 603707) held its 15th meeting of the 5th board of directors on October 24, 2025, to review the proposal for the company's Q3 2025 report [1] - For the year 2024, Jianyou Co., Ltd.'s revenue composition is 99.85% from the pharmaceutical manufacturing industry and 0.15% from other businesses [1] - As of the report date, Jianyou Co., Ltd. has a market capitalization of 15.6 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion USD this year [1] - It highlights a conversation with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine while the primary market faces fundraising challenges [1]